(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
Go With The Breeze: Grand Paragliding Spots On the planet- Famous Restroom Beautifying Styles For 2024
- Struggling to keep your New Year's resolutions? Here's how to keep yourself on track
- 5 Different ways Macintosh is Prepared to Overwhelm Gaming, Even Against Windows
- Well known Travel Booking Locales: What's Your Pick?
- Vote In favor of Your Favored Language Learning Applications
- Scientists document a death from a meat allergy tied to certain ticks
- Grasping the Commencement of Criminal Cases: An Extensive Outline
- Promising Speculation Bearings for Portfolio Development in 2024
